Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Airway Obstruction D000402 13 associated lipids
Stomach Ulcer D013276 75 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Stomach Diseases D013272 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Lung Diseases D008171 37 associated lipids
Sarcoidosis D012507 13 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Colitis D003092 69 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Genital Diseases, Male D005832 3 associated lipids
Sexually Transmitted Diseases D012749 4 associated lipids
Fatty Liver D005234 48 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Arthritis D001168 41 associated lipids
Abscess D000038 13 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Osteitis D010000 10 associated lipids
Dog Diseases D004283 5 associated lipids
Osteomyelitis D010019 10 associated lipids
Coronary Disease D003327 70 associated lipids
Pancreatitis D010195 10 associated lipids
Acne Vulgaris D000152 35 associated lipids
Skin Ulcer D012883 6 associated lipids
Eyelid Diseases D005141 4 associated lipids
Multiple Myeloma D009101 13 associated lipids
Pain, Postoperative D010149 13 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Corneal Opacity D003318 3 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Crohn Disease D003424 12 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Sinusitis D012852 9 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Penile Diseases D010409 2 associated lipids
Acquired Immunodeficiency Syndrome D000163 12 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Cross Infection D003428 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Wound Infection D014946 12 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cat-Scratch Disease D002372 4 associated lipids
Birth Weight D001724 23 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cytomegalovirus Infections D003586 7 associated lipids
Periodontitis D010518 22 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Vomiting D014839 21 associated lipids
Fever D005334 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Pregnancy Complications, Infectious D011251 11 associated lipids
Toxoplasmosis D014123 9 associated lipids
Toxoplasmosis, Congenital D014125 2 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Shock, Septic D012772 11 associated lipids
Syphilis D013587 6 associated lipids
Hearing Disorders D006311 10 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Infant, Newborn, Diseases D007232 9 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Uterine Cervicitis D002575 3 associated lipids
Neutropenia D009503 15 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Urticaria D014581 13 associated lipids
Escherichia coli Infections D004927 17 associated lipids
Respiratory Tract Infections D012141 4 associated lipids
Agammaglobulinemia D000361 4 associated lipids
Corneal Edema D015715 3 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
HIV Seropositivity D006679 15 associated lipids
Endophthalmitis D009877 12 associated lipids
Enteritis D004751 8 associated lipids
Leprosy D007918 8 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Bellon H et al. Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options. 2017 Transpl. Int. pmid:28078769
Geudens N et al. Azithromycin reduces airway inflammation in a murine model of lung ischaemia reperfusion injury. 2008 Transpl. Int. pmid:18435685
Verleden GM et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts? 2009 Transpl. Int. pmid:19490538
Verleden GM et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. 2011 Transpl. Int. pmid:21401732
Verleden GM et al. Current views on chronic rejection after lung transplantation. 2015 Transpl. Int. pmid:25857869
Kwun WH et al. Effect of azithromycin in the treartment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. 2003 Transplant. Proc. pmid:12591416
Nafar M et al. A comparison between the efficacy of systemic and local azithromycin therapy in treatment of cyclosporine induced gingival overgrowth in kidney transplant patients. 2003 Transplant. Proc. pmid:14612094
Puig JM et al. Treatment of gingival hyperplasia secondary to cyclosporine by the new macrolide azithromycin. 1997 Transplant. Proc. pmid:9270772
Wirnsberger GH et al. Effect of antibiotic treatment with azithromycin on cyclosporine A-induced gingival hyperplasia among renal transplant recipients. 1998 Transplant. Proc. pmid:9723411
Boran M et al. Improvement in cyclosporine A associated gingival hyperplasia with azithromycin therapy. 1996 Transplant. Proc. pmid:8769234
Citterio F et al. Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe. 2001 Transplant. Proc. pmid:11377476
Verleden GM et al. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. 2009 Transplant. Proc. pmid:19545735
Tokgöz B et al. Effects of azithromycin on cyclosporine-induced gingival hyperplasia in renal transplant patients. 2004 Transplant. Proc. pmid:15621128
Shullo MA et al. Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: a case report. 2010 Transplant. Proc. pmid:20620540
Lendermon EA et al. Azithromycin Fails to Prevent Accelerated Airway Obliteration in T-bet Mouse Lung Allograft Recipients. 2018 Transplant. Proc. pmid:29880387
Nash MM and Zaltzman JS Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients. 1998 Transplantation pmid:9665078
Verleden GM and Dupont LJ Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. 2004 Transplantation pmid:15167610
Imai N et al. A case of Campylobacter enteritis in a renal transplant recipient. 2013 Transplantation pmid:23774778
Vos R et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. 2012 Transplantation pmid:22461039
Gottlieb J et al. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. 2008 Transplantation pmid:18192909
Verleden SE et al. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ? 2013 Transplantation pmid:23425818
Wirnsberger GH and Pfragner R Comment on "Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients" by Nash and Zaltzman. 1999 Transplantation pmid:10342326
Requena-Méndez A et al. Enteric fever in Barcelona: Changing patterns of importation and antibiotic resistance. Travel Med Infect Dis pmid:27890811
Dave J et al. Trends in antibiotic susceptibility of enteric fever isolates in East London. Travel Med Infect Dis pmid:25964222
Baneke A Review: Targeting trachoma: Strategies to reduce the leading infectious cause of blindness. 2012 Travel Med Infect Dis pmid:22326056
Swanson RN et al. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. 2005 Treat Respir Med pmid:15725048
Cymbala AA et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. 2005 Treat Respir Med pmid:15813663
Zervos M et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. 2004 Treat Respir Med pmid:15606222
What's in the water? 1995 Mar-Apr Treat Rev pmid:11362299
Azithro once a week for MAC. 1998 TreatmentUpdate pmid:11365625
Infection fighters. MAC prevention takes a holiday. 2000 TreatmentUpdate pmid:12132450
Noedl H ABC - antibiotics-based combinations for the treatment of severe malaria? 2009 Trends Parasitol. pmid:19819757
Chang AB et al. Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial. 2012 Trials pmid:22937736
Pokharel S et al. Co-trimoxazole versus azithromycin for the treatment of undifferentiated febrile illness in Nepal: study protocol for a randomized controlled trial. 2017 Trials pmid:28969659
Uzun S et al. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. 2012 Trials pmid:22682323
Chang AB et al. Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial. 2013 Trials pmid:23421781
Chang AB et al. Randomized placebo-controlled trial on azithromycin to reduce the morbidity of bronchiolitis in Indigenous Australian infants: rationale and protocol. 2011 Trials pmid:21492416
Brittain C et al. Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial. 2016 Trials pmid:27881151
Bandyopadhyay R et al. Effectiveness of treatment regimens for Typhoid fever in the nalidixic acid-resistant S. typhi (NARST) era in South India. 2018 Trop Doct pmid:29495943
Rajapakse S et al. Drug treatment of scrub typhus. 2011 Trop Doct pmid:21172901
Fegan D et al. Resurgence of yaws in Tanna, Vanuatu: time for a new approach? 2010 Trop Doct pmid:20305095
Mahajan SK et al. Scrub typhus and malaria co-infection causing severe sepsis. 2014 Trop Doct pmid:24249027
Fegan D et al. Tropical leg ulcers in children: more than yaws. 2016 Trop Doct pmid:26289420
Kuper H et al. Participatory evaluations of trachoma control programmes in eight countries. 2005 Trop. Med. Int. Health pmid:16045463
Wong RP et al. In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea. 2010 Trop. Med. Int. Health pmid:20070627
Edwards T et al. Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin. 2008 Trop. Med. Int. Health pmid:18282237
Luntamo M et al. The effect of antenatal monthly sulphadoxine-pyrimethamine, alone or with azithromycin, on foetal and neonatal growth faltering in Malawi: a randomised controlled trial. 2013 Trop. Med. Int. Health pmid:23432801
Hart JD et al. Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. 2014 Trop. Med. Int. Health pmid:24433194
Chico RM and Chandramohan D Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. 2011 Trop. Med. Int. Health pmid:21477099
de Vries PI et al. Short course of azithromycin/artesunate against falciparum malaria: no full protection against recrudescence. 1999 Trop. Med. Int. Health pmid:10402979